TDMQ20, a Specific Copper Chelator, Reduces Memory Impairments in Alzheimer's Disease Mouse Models

Area of Science:

• Neuroscience
• Bioinorganic Chemistry
• Pharmacology

Background:

• Alzheimer's disease (AD) pathogenesis involves amyloid and tau, but redox metal ion dysregulation is also a key therapeutic target.
• Copper-amyloid complexes catalyze oxidative stress, contributing to AD progression.
• Targeting copper homeostasis offers a novel therapeutic strategy for AD.

Purpose of the Study:

• To design and evaluate copper(II) chelators (TDMQs) for regulating brain copper homeostasis and inhibiting copper-catalyzed oxidative stress in AD.
• To assess the therapeutic efficacy of TDMQ20 in reversing cognitive and behavioral impairments across diverse AD murine models.

Main Methods:

• Development of TDMQs based on copper bioinorganic chemistry.
• Administration of TDMQ20 orally to nontransgenic mice with induced cognitive impairment (icv-CuAβ, hippo-CuAβ) and to transgenic 5XFAD mice.
• Evaluation of cognitive status using the novel object recognition (NOR) test and assessment of oxidative stress markers.

Main Results:

• TDMQ20 fully reversed cognitive and behavioral impairments in all tested AD murine models.
• A 16-day treatment improved cognitive status in icv-CuAβ and hippo-CuAβ mice.
• A 3-month treatment improved behavioral outcomes in 5XFAD mice, with reduced cortical oxidative stress.

Conclusions:

• TDMQ20 demonstrates significant therapeutic potential for Alzheimer's disease by restoring copper homeostasis and mitigating oxidative damage.
• The hippo-CuAβ model is a robust tool for evaluating early-stage memory deficit interventions.
• This study validates copper chelation as a promising therapeutic avenue for Alzheimer's disease.